Cancer treatment systems maker BSD Medical Corp (BSDM) will showcase its MicroThermX Microwave Ablation system for soft tissue ablation (destruction) at the annual scientific meeting of the Society of Interventional Radiology (“SIR”), scheduled to be held in Chicago between March 26-March 31, 2011.
SIR is the largest meeting in the U.S. for minimally invasive interventional radiology/oncology products with nearly 5,300 physicians, scientists and health professionals attending from across the globe. BSD Medical reckons the SIR meet as an important platform to bolster the profile of its microwave ablation products and highlight the significant benefits of the MicroThermX system to a large pool of international interventional radiologists.
BSD Medical introduced the innovative MicroThermX system in the U.S. in December 2010. Subsequently, the Utah-based company successfully rolled out its first MicroThermX system in Europe in January 2011. BSD Medical shipped the product to Med-Italia Biomedica (Med-Italia), a leading distributor of products in the interventional radiology/oncology market.
Moreover, Beaumont Hospital in Michigan and Rhode Island Hospital became among the first in the U.S., in February 2011, to use the MicroThermX system. BSD Medical is in the final phase of implementing a dedicated global distribution network and expanding its marketing and sales force to support the worldwide roll-out of its MicroThermX products. The company is using the network of specialty distribution firms, which market products in the interventional radiology area.
The MicroThermX system leverages BSD Medical’s proprietary synchronous phased array technology to deliver precision-guided microwave energy to ablate soft tissues using a single-patient-use disposable antenna.
The minimally-invasive MicroThermX system has been developed to provide treatments as a stand-alone therapy and has applications in open surgical and percutaneous (via needle-puncture of the skin) ablation procedures. As such, it can be used by both surgeons and interventional radiologists.
Currently, radiofrequency (“RF”) energy is most commonly used to deliver ablation therapy in the interventional oncology market. MicroThermX offers several key advantages over the legacy RF-based systems including delivery of wider ablation zones in less time employing microwave energy.
BSD Medical competes with established players like Boston Scientific (BSX) and Angiodynamics (ANGO) in the thermal ablation market. The global market potential for soft tissue ablation has been estimated to exceed $2.3 billion, offering a significant opportunity for BSD Medical.
ANGIODYNAMICS (ANGO): Free Stock Analysis Report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
Zacks Investment Research
